The Drug Addiction Treatment Market size was estimated at USD 18.81 billion in 2023 and is expected to reach USD 33.17 billion by 2031 at a CAGR of 7.35% during the forecast period of 2024-2031.
On a global scale, drug overdose is one of the leading causes of death. According to the Centers for Disease Control and Prevention (CDC), over 91,000 people have died in the United States as a result of a drug overdose. According to data, drug overdose and regular intake of addictive substances have a negative impact on users' mental health, with the highest prevalence of Intermittent Explosive disorder (IED) and Attention-Deficit Hyperactivity Disorder (ADHD). Furthermore, the increasing number of campaigns and efforts launched by governments and other organizations to increase awareness about drug addiction, including the consequences of drug usage and dealing with drug-related issues, is boosting market revenue growth.
Get more information on Drug Addiction Treatment Market - Request Sample Report
Furthermore, official interventions offer a variety of distinct ideas on how to rehabilitate addicts, eliminate stigma associated with substance use, and starve the underground markets. Many countries have effectively updated their drug laws, enforcement strategies, and approaches to addiction. Another factor driving market revenue growth is the increasing use of Medication-Assisted Treatments (MATs) to treat opioid use disorders (OUDs). Several firms are pushing the use of pharmacological therapy in novel and more efficient ways to treat OUD. The US Food and Drug Administration (FDA) has issued draft recommendations supporting greater research and development of novel Medication-Assisted Treatment (MAT) drugs for opioid use disorder, which has recently become a severe healthcare epidemic in the United States.
According to the Centers for Disease Control and Prevention (CDC), approximately 114 people die each day from drug overdoses, and 6,748 people seek treatment in the Emergency Department (ED) for drug abuse or misuse in the United States. Furthermore, pharmaceuticals are responsible for approximately nine out of every 10 poisoning deaths. Prescription drug misuse and non-medical use are serious public health hazards all over the world, therefore prescription opioid painkillers are killing more people every year.
DRIVERS
The rising prevalence of drug-addicted individuals is a primary element driving market revenue growth.
The rising prevalence of patients with drug addiction and the rising number of deaths connected to Substance-Use Disorders (SUDs) are important factors driving individuals' demand for help and treatment, driving revenue growth in the global drug addiction treatment market. Through statistical knowledge of drug and alcohol abuse, tremendous progress has been made in the prevention and treatment of substance abuse over the last three decades. Furthermore, drug overdose deaths have been rapidly increasing and are now among the leading causes of death worldwide, owing to users' growing reliance on prescription medicines and a decrease in the perceived toxicity of specific drug classes.
RESTRAIN
Reluctance among drug-use disorder patients is a primary factor limiting market revenue growth.
OPPORTUNITY
Increased Government Initiatives and Funding for Addiction Treatment Laboratories
The recent addiction problem has increased the need to invest in integrated R&D initiatives focused on addiction treatment and rehabilitation. Despite the fact that the number of research efforts connected to addiction difficulties has expanded at an astonishing rate, players operating in the current addiction treatment market landscape are progressively finding innovative strategies to incorporate these results into real-world care delivery.
CHALLENGES
Reluctance Among Drug-Use Disorder Patients.
According to the study of reports and a news the russia ukraine war badly impected in ukraine, nongovernmental organizations (NGOs) primarily provided interventions in Ukraine to prevent bad health outcomes among those who inject drugs. In May 2021, approximately 15,700 drug users were receiving opioid agonist treatment, with women accounting for 16% of the total. By February 2022, that figure had risen to 17,210 people. The majority of those undergoing opioid agonist treatment in 2021 were men, who were less likely to have fled the nation since the conflict began. This was thought to be the number of people receiving such services throughout Eastern Europe and Central Asia. Ukraine was also the only country in Eastern Europe where opioid users could obtain naloxone without a prescription for overdose prevention and management.
GSMSG first assembled a 10-person combat surgery team, which reached Ukraine nine days after Russia invaded. Their mission was to train any interested and capable Ukrainian citizen in combat casualty care, to provide combat trauma care training and surgical support to the civilian Ukrainian medical system, and to provide combat care training to Ukrainian military personnel and military physicians. GSMSG rotated additional teams of surgeons with experience in trauma, surgical critical care, burn, plastics, orthopaedics, vascular, and neurosurgery. GSMSG rotated additional teams of surgeons with experience in trauma, surgical critical care, burn, plastics, orthopaedics, vascular, and neurosurgery. GSMSG also created a collaboration with the Ukrainian Armed Forces, Ukrainian Special Operations Forces (UKRSOF), and Ukrainian Special Surgical Groups, with the support of the Ukrainian Ministry of Defense and Ministry of Health, to offer damage control surgery as close to the scene as possible. as 0.5 kilometers from active action with Russian forces. Since their arrival in Ukraine, GSMSG team members have trained over 20,000 Ukrainian civilians and military personnel. They have also provided surgical support to over 300 patients, some of whom are within 10 kilometers of the battle lines.
IMPACT OF ONGOING RECESSION
Healthcare Spending Cuts During a recession, governments and individuals may face financial constraints, resulting in reduced healthcare budgets. Funding for drug addiction treatment programs and services may be jeopardized, perhaps leading to a reduction in treatment options. Services are in high demand. Economic downturns can cause stress, worry, and mental health problems, thereby boosting the demand for drug addiction treatment services as people struggle with financial difficulties. During a recession, healthcare organizations may need to prioritize important services and critical medical needs. This could have an impact on how money and attention are allocated to drug addiction treatment programs.Impact on Public and Nonprofit Programs During a recession, government funding for public drug addiction treatment programs may be curtailed, reducing the availability of inexpensive treatment options. Nonprofit organizations and charity foundations may confront similar difficulties in generating cash for their projects.
By Treatment
Therapy
Medication
Others
By Types
Opioid Addiction
Benzodiazepine Addiction
Barbiturate Addiction
Others
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others
By End-Users
Hospitals
Specialty Clinics
Others
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
North America has suffered substantial opioid addiction concerns, particularly in the United States and Canada. Methadone and buprenorphine, two opioid replacement treatments, are commonly utilized. The region has a well-developed healthcare system that includes both public and private treatment facilities. Harm reduction measures and access to naloxone for overdose reversal have received increased attention. Opioid addiction is a problem in some parts of Europe, but there is also a wide spectrum of other substance abuse disorders. Treatment techniques vary by country, including medication-assisted treatment and psychological therapies. In several European countries, harm reduction techniques such as needle exchange programs and supervised injection facilities are widespread. The Asia-Pacific region is confronted with issues connected to opioid addiction, amphetamine use, and other narcotics. Access to treatment varies greatly among countries due to disparities in healthcare facilities and resources. Treatment-seeking behavior and methods of addiction treatment can be influenced by cultural and social factors.
Need any customization research on Drug Addiction Treatment Market - Enquiry Now
The major key players are Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Abbott, BD, Johnson & Johnson Services, Inc., GSK Plc., Bayer AG, Zimmer Biomet and Other Players.
Pfizer, Inc: In 2022, announced a new strategic relationship with Alex Therapeutics to personalize treatment using digital therapeutics and use the latter company's Al-based platform to provide Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) to nicotine addiction patients.
| Report Attributes | Details |
| Market Size in 2023 | US$ 18.81 Bn |
| Market Size by 2031 | US$ 33.17 Bn |
| CAGR | CAGR of 7.35% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Therapy, Medication, Others) • By Types (Opioid Addiction, Benzodiazepine Addiction, Barbiturate Addiction, Others) • By Route of Administration (Oral, Parenteral, Others) • By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others) • By End-Users (Hospitals, Specialty Clinics, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Abbott, BD, Johnson & Johnson Services, Inc., GSK Plc., Bayer AG, Zimmer Biomet |
| Key Drivers | • The rising prevalence of drug-addicted individuals is a primary element driving market revenue growth. |
| Market Restraints | • Reluctance among drug-use disorder patients is a primary factor limiting market revenue growth. |
Ans: The Drug Addiction Treatment Market is expected to grow at 7.35% CAGR from 2024 to 2031.
Ans: The Drug Addiction Treatment Market is anticipated to reach USD 33.17 Bn By 2031.
Ans: The leading participants in the, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Abbott, BD , Johnson & Johnson Services, Inc.
Ans: The counseling and behavioral therapies category is predicted to have the highest revenue share during the projection period.
Ans: Yes, you may request customization based on your company's needs.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Ukraine- Russia War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Drug Addiction Treatment Market Segmentation, By Treatment
8.1 Therapy
8.2 Medication
8.3 Others
9. Drug Addiction Treatment Market Segmentation, By Types
9.1 Opioid Addiction
9.2 Benzodiazepine Addiction
9.3 Barbiturate Addiction
9.4 Others
10. Drug Addiction Treatment Market Segmentation, By Route of Administration
10.1 Oral
10.2 Parenteral
10.3 Others
11. Drug Addiction Treatment Market Segmentation, By Distribution Channel
11.1 Hospital Pharmacy
11.2 Retail Pharmacy
11.3 Online Pharmacies
11.4 Others
12. Drug Addiction Treatment Market Segmentation, By End-Users
12.1 Hospitals
12.2 Specialty Clinics
12.3 Others
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 North America Drug Addiction Treatment Market by country
13.2.2North America Drug Addiction Treatment Market by Drug Type
13.2.3 North America Drug Addiction Treatment Market by Treatment
13.2.4 North America Drug Addiction Treatment Market by End-user
13.2.5 USA
13.2.5.1 USA Drug Addiction Treatment Market by Drug Tyoe
13.2.5.2 USA Drug Addiction Treatment Market by Treatment
13.2.5.3 USA Drug Addiction Treatment Market by End-user
13.2.6 Canada
13.2.6.1 Canada Drug Addiction Treatment Market by Drug Tyoe
13.2.6.2 Canada Drug Addiction Treatment Market by Treatment
13.2.6.3 Canada Drug Addiction Treatment Market by End-user
13.2.7 Mexico
13.2.7.1 Mexico Drug Addiction Treatment Market by Drug Tyoe
13.2.7.2 Mexico Drug Addiction Treatment Market by Treatment
13.2.7.3 Mexico Drug Addiction Treatment Market by End-user
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Eastern Europe Drug Addiction Treatment Market by country
13.3.1.2 Eastern Europe Drug Addiction Treatment Market by Drug Tyoe
13.3.1.3 Eastern Europe Drug Addiction Treatment Market by Treatment
13.3.1.4 Eastern Europe Drug Addiction Treatment Market by End-user
13.3.1.5 Poland
13.3.1.5.1 Poland Drug Addiction Treatment Market by Drug Tyoe
13.3.1.5.2 Poland Drug Addiction Treatment Market by Treatment
13.3.1.5.3 Poland Drug Addiction Treatment Market by End-user
13.3.1.6 Romania
13.3.1.6.1 Romania Drug Addiction Treatment Market by Drug Tyoe
13.3.1.6.2 Romania Drug Addiction Treatment Market by Treatment
13.3.1.6.4 Romania Drug Addiction Treatment Market by End-user
13.3.1.7 Turkey
13.3.1.7.1 Turkey Drug Addiction Treatment Market by Drug Tyoe
13.3.1.7.2 Turkey Drug Addiction Treatment Market by Treatment
13.3.1.7.3 Turkey Drug Addiction Treatment Market by End-user
13.3.1.8 Rest of Eastern Europe
13.3.1.8.1 Rest of Eastern Europe Drug Addiction Treatment Market by Drug Tyoe
13.3.1.8.2 Rest of Eastern Europe Drug Addiction Treatment Market by Treatment
13.3.1.8.3 Rest of Eastern Europe Drug Addiction Treatment Market by End-user
13.3.2 Western Europe
13.3.2.1 Western Europe Drug Addiction Treatment Market by Drug Tyoe
13.3.2.2 Western Europe Drug Addiction Treatment Market by Treatment
13.3.2.3 Western Europe Drug Addiction Treatment Market by End-user
13.3.2.4 Germany
13.3.2.4.1 Germany Drug Addiction Treatment Market by Drug Tyoe
13.3.2.4.2 Germany Drug Addiction Treatment Market by Treatment
13.3.2.4.3 Germany Drug Addiction Treatment Market by End-user
13.3.2.5 France
13.3.2.5.1 France Drug Addiction Treatment Market by Drug Tyoe
13.3.2.5.2 France Drug Addiction Treatment Market by Treatment
13.3.2.5.3 France Drug Addiction Treatment Market by End-user
13.3.2.6 UK
13.3.2.6.1 UK Drug Addiction Treatment Market by Drug Tyoe
13.3.2.6.2 UK Drug Addiction Treatment Market by Treatment
13.3.2.6.3 UK Drug Addiction Treatment Market by End-user
13.3.2.7 Italy
13.3.2.7.1 Italy Drug Addiction Treatment Market by Drug Tyoe
13.3.2.7.2 Italy Drug Addiction Treatment Market by Treatment
13.3.2.7.3 Italy Drug Addiction Treatment Market by End-user
13.3.2.8 Spain
13.3.2.8.1 Spain Drug Addiction Treatment Market by Drug Tyoe
13.3.2.8.2 Spain Drug Addiction Treatment Market by Treatment
13.3.2.8.3 Spain Drug Addiction Treatment Market by End-user
13.3.2.9 Netherlands
13.3.2.9.1 Netherlands Drug Addiction Treatment Market by Drug Tyoe
13.3.2.9.2 Netherlands Drug Addiction Treatment Market by Treatment
13.3.2.9.3 Netherlands Drug Addiction Treatment Market by End-user
13.3.2.10 Switzerland
13.3.2.10.1 Switzerland Drug Addiction Treatment Market by Drug Tyoe
13.3.2.10.2 Switzerland Drug Addiction Treatment Market by Treatment
13.3.2.10.3 Switzerland Drug Addiction Treatment Market by End-user
13.3.2.13.1 Austria
13.3.2.13.2 Austria Drug Addiction Treatment Market by Drug Tyoe
13.3.2.13.3 Austria Drug Addiction Treatment Market by Treatment
13.3.2.13.4 Austria Drug Addiction Treatment Market by End-user
13.3.2.12 Rest of Western Europe
13.3.2.12.1 Rest of Western Europe Drug Addiction Treatment Market by Drug Tyoe
13.3.2.12.2 Rest of Western Europe Drug Addiction Treatment Market by Treatment
13.3.2.12.3 Rest of Western Europe Drug Addiction Treatment Market by End-user
13.4 Asia-Pacific
13.4.1 Asia-Pacific Drug Addiction Treatment Market by country
13.4.2 Asia-Pacific Drug Addiction Treatment Market by Drug Tyoe
13.4.3 Asia-Pacific Drug Addiction Treatment Market by Treatment
13.4.4 Asia-Pacific Drug Addiction Treatment Market by End-user
13.4.5 China
13.4.5.1 China Drug Addiction Treatment Market by Drug Tyoe
13.4.5.2 China Drug Addiction Treatment Market by Treatment
13.4.5.3 China Drug Addiction Treatment Market End-user
13.4.6 India
13.4.6.1 India Drug Addiction Treatment Market by Drug Tyoe
13.4.6.2 India Drug Addiction Treatment Market by Treatment
13.4.6.3 India Drug Addiction Treatment Market by End-user
13.4.7 Japan
13.4.7.1 Japan Drug Addiction Treatment Market by Drug Tyoe
13.4.7.2 Japan Drug Addiction Treatment Market by Treatment
13.4.7.3 Japan Drug Addiction Treatment Market by End-user
13.4.8 South Korea
13.4.8.1 South Korea Drug Addiction Treatment Market by Drug Tyoe
13.4.8.2 South Korea Drug Addiction Treatment Market by Treatment
13.4.8.3 South Korea Drug Addiction Treatment Market by End-user
13.4.9 Vietnam
13.4.9.1 Vietnam Drug Addiction Treatment Market by Drug Tyoe
13.4.9.2 Vietnam Drug Addiction Treatment Market by Treatment
13.4.9.3 Vietnam Drug Addiction Treatment Market by End-user
13.4.10 Singapore
13.4.10.1 Singapore Drug Addiction Treatment Market by Drug Tyoe
13.4.10.2 Singapore Drug Addiction Treatment Market by Treatment
13.4.10.3 Singapore Drug Addiction Treatment Market by End-user
13.4.13 Australia
13.4.13.1 Australia Drug Addiction Treatment Market by Drug Tyoe
13.4.13.2 Australia Drug Addiction Treatment Market by Treatment
13.4.13.3 Australia Drug Addiction Treatment Market by End-user
13.4.12 Rest of Asia-Pacific
13.4.12.1 Rest of Asia-Pacific Drug Addiction Treatment Market by Drug Tyoe
13.4.12.2 Rest of Asia-Pacific Drug Addiction Treatment Market by Treatment
13.4.12.3 Rest of Asia-Pacific Drug Addiction Treatment Market by End-user
13.5 Middle East & Africa
13.5.1 Middle East
13.5.1.1 Middle East Drug Addiction Treatment Market by country
13.5.1.2 Middle East Drug Addiction Treatment Market by Drug Tyoe
13.5.1.3 Middle East Drug Addiction Treatment Market by Treatment
13.5.1.4 Middle East Drug Addiction Treatment Market by End-user
13.5.1.5 UAE
13.5.1.5.1 UAE Drug Addiction Treatment Market by Drug Tyoe
13.5.1.5.2 UAE Drug Addiction Treatment Market by Treatment
13.5.1.5.3 UAE Drug Addiction Treatment Market by End-user
13.5.1.6 Egypt
13.5.1.6.1 Egypt Drug Addiction Treatment Market by Drug Tyoe
13.5.1.6.2 Egypt Drug Addiction Treatment Market by Treatment
13.5.1.6.3 Egypt Drug Addiction Treatment Market by End-user
13.5.1.7 Saudi Arabia
13.5.1.7.1 Saudi Arabia Drug Addiction Treatment Market by Drug Tyoe
13.5.1.7.2 Saudi Arabia Drug Addiction Treatment Market by Treatment
13.5.1.7.3 Saudi Arabia Drug Addiction Treatment Market by End-user
13.5.1.8 Qatar
13.5.1.8.1 Qatar Drug Addiction Treatment Market by Drug Tyoe
13.5.1.8.2 Qatar Drug Addiction Treatment Market by Treatment
13.5.1.8.3 Qatar Drug Addiction Treatment Market by End-user
13.5.1.9 Rest of Middle East
13.5.1.9.1 Rest of Middle East Drug Addiction Treatment Market by Drug Tyoe
13.5.1.9.2 Rest of Middle East Drug Addiction Treatment Market by Treatment
13.5.1.9.3 Rest of Middle East Drug Addiction Treatment Market by End-user
13.5.2 Africa
13.5.2.1 Africa Drug Addiction Treatment Market by country
13.5.2.2 Africa Drug Addiction Treatment Market by Drug Tyoe
13.5.2.3 Africa Drug Addiction Treatment Market by Treatment
13.5.2.4 Africa Drug Addiction Treatment Market by End-user
13.5.2.5 Nigeria
13.5.2.5.1 Nigeria Drug Addiction Treatment Market by Drug Tyoe
13.5.2.5.2 Nigeria Drug Addiction Treatment Market by Treatment
13.5.2.5.3 Nigeria Drug Addiction Treatment Market by End-user
13.5.2.6 South Africa
13.5.2.6.1 South Africa Drug Addiction Treatment Market by Drug Tyoe
13.5.2.6.2 South Africa Drug Addiction Treatment Market by Treatment
13.5.2.6.3 South Africa Drug Addiction Treatment Market by End-user
13.5.2.7 Rest of Africa
13.5.2.7.1 Rest of Africa Drug Addiction Treatment Market by Drug Tyoe
13.5.2.7.2 Rest of Africa Drug Addiction Treatment Market by Treatment
13.5.2.7.3 Rest of Africa Drug Addiction Treatment Market by End-user
13.6 Latin America
13.6.1 Latin America Drug Addiction Treatment Market by country
13.6.2 Latin America Drug Addiction Treatment Market by Drug Tyoe
13.6.3 Latin America Drug Addiction Treatment Market by Treatment
13.6.4 Latin America Drug Addiction Treatment Market by End-user
13.6.5 Brazil
13.6.5.1 Brazil America Drug Addiction Treatment Market by Drug Tyoe
13.6.5.2 Brazil America Drug Addiction Treatment Market by Treatment
13.6.5.3 Brazil America Drug Addiction Treatment Market by End-user
13.6.6 Argentina
13.6.6.1 Argentina America Drug Addiction Treatment Market by Drug Tyoe
13.6.6.2 Argentina America Drug Addiction Treatment Market by Treatment
13.6.6.3 Argentina America Drug Addiction Treatment Market by End-user
13.6.7 Colombia
13.6.7.1 Colombia America Drug Addiction Treatment Market by Drug Tyoe
13.6.7.2 Colombia America Drug Addiction Treatment Market by Treatment
13.6.7.3 Colombia America Drug Addiction Treatment Market by End-user
13.6.8 Rest of Latin America
13.6.8.1 Rest of Latin America Drug Addiction Treatment Market by Drug Tyoe
13.6.8.2 Rest of Latin America Drug Addiction Treatment Market by Treatment
13.6.8.3 Rest of Latin America Drug Addiction Treatment Market by End-user
14. Company profile
14.1 Takeda Pharmaceutical Company Limited.
14.1.1 Company Overview
14.1.2 Financials
14.1.3 Product/Services/Offerings
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 , F. Hoffmann-La Roche Ltd.
14.2.1 Company Overview
14.2.2 Financials
14.2.3 Product/Services/Offerings
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Abbott.
14.3.1 Company Overview
14.3.2 Financials
14.3.3 Product/Services/Offerings
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Medtronic.
14.4.1 Company Overview
14.4.2 Financials
14.4.3 Product/Services/Offerings
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5Abbott, BD .
14.5.1 Company Overview
14.5.2 Financials
14.5.3 Product/Services/Offerings
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 Johnson & Johnson Services.
14.6.1 Company Overview
14.6.2 Financials
14.6.3 Product/Services/Offerings
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 GSK Plc.
14.7.1 Company Overview
14.7.2 Financials
14.7.3 Product/Services/Offerings
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Bayer AG.
14.8.2 Financials
14.8.3 Product/Services/Offerings
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 Zimmer Biomet
14.9.1 Company Overview
14.9.2 Financials
14.9.3 Product/Services/Offerings
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Stryker Corporation.
14.10.1 Company Overview
14.10.2 Financials
14.10.3 Product/Services/Offerings
14.10.4 SWOT Analysis
14.10.5 The SNS View
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. Use Case and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Echocardiography Market was estimated at US$ 2.01 billion in 2023 and is expected to reach US$ 3.54 billion by 2031 and is anticipated to increase at a CAGR of 7.21% predicted for the forecast period of 2024-2031.
The Blood Glucose Monitoring Device Market Size was valued at USD 13.42 billion in 2023, and is expected to reach USD 25.28 billion by 2031, and grow at a CAGR of 8.24% over the forecast period 2024-2031.
The Anti-Fungal Treatment Market Size was valued at USD 16.83 billion in 2023 and is expected to reach USD 23.70 billion by 2032 and grow at a CAGR of 3.88% over the forecast period 2024-2032.
The Allergic Conjunctivitis Market size was valued at USD 3.03 billion in 2023 and is expected to reach USD 4.90 billion by 2032 with an emerging CAGR of 5.7% Over the Forecast Period of 2024-2032.
The Neonatal Respiratory Care Devices Market size was valued at USD 1.82 billion In 2023 & is estimated to reach USD 3.10 billion by 2032 and increase at a compound annual growth rate of 6.1% between 2024 and 2032.
The Peripheral Neuropathy Market valued USD 1.48 billion in 2023, estimated to surpass USD 2.38 billion by 2032 with a compound annual growth rate of 5.46% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
